• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.COVID-19 住院患者使用托珠单抗的疗效：CORIMUNO-TOCI-1 随机临床试验的随访。
JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.
2
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
3
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
4
Efficacy of tocilizumab treatment in severely ill COVID-19 patients.托珠单抗治疗重症 COVID-19 患者的疗效。
Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.
5
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
6
[COVID-19: Still a place for tocilizumab?].[新型冠状病毒肺炎：托珠单抗仍有一席之地？]
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
7
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
8
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.探讨 COVID-19 肺炎进展为细胞因子风暴综合征的特征：来自意大利单中心关于托珠单抗与标准治疗比较的研究结果。
J Clin Virol. 2020 Aug;129:104444. doi: 10.1016/j.jcv.2020.104444. Epub 2020 May 15.
9
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
10
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.COVIDOSE：托珠单抗低剂量治疗非重症 COVID-19 肺炎的 II 期临床试验。
Clin Pharmacol Ther. 2021 Mar;109(3):688-696. doi: 10.1002/cpt.2117. Epub 2020 Dec 10.

引用本文的文献

1
Global maternal mortality associated with SARS-CoV-2 infection: a systematic review and meta-analysis.与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关的全球孕产妇死亡率：一项系统评价和荟萃分析。
BMJ Glob Health. 2025 Apr 21;10(4):e015815. doi: 10.1136/bmjgh-2024-015815.
2
Senescence as a therapeutic target in cancer and age-related diseases.衰老作为癌症和年龄相关疾病的治疗靶点。
Nat Rev Drug Discov. 2025 Jan;24(1):57-71. doi: 10.1038/s41573-024-01074-4. Epub 2024 Nov 15.
3
Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients.临床表型分析揭示了危重症 COVID-19 患者中皮质类固醇治疗与生存之间的异质关联。
Intensive Care Med. 2024 Nov;50(11):1884-1896. doi: 10.1007/s00134-024-07593-3. Epub 2024 Aug 26.
4
COVID-19 Pneumonia and Cytokine Storm Syndrome.新型冠状病毒肺炎及细胞因子风暴综合征
Adv Exp Med Biol. 2024;1448:307-319. doi: 10.1007/978-3-031-59815-9_22.
5
Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.托珠单抗与单独的标准治疗相比，可显著降低住院 COVID-19 患者的 C 反应蛋白水平。
Microbiol Spectr. 2024 Jun 4;12(6):e0249823. doi: 10.1128/spectrum.02498-23. Epub 2024 Apr 30.
6
The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study.中性粒细胞减少性发热与2019冠状病毒病的临床特征、治疗及预后：多中心TEOS研究结果
Sci Rep. 2024 Mar 3;14(1):5218. doi: 10.1038/s41598-024-55886-w.
7
Application of LRG mechanism in normal pressure hydrocephalus.LRG机制在正常压力脑积水中的应用。
Heliyon. 2023 Dec 16;10(1):e23940. doi: 10.1016/j.heliyon.2023.e23940. eCollection 2024 Jan 15.
8
Inhaled beclomethasone in the treatment of early COVID-19: a double-blind, placebo-controlled, randomised, hospital-based trial in Sri Lanka.吸入用倍氯米松治疗早期 COVID-19：斯里兰卡一项基于医院的双盲、安慰剂对照、随机对照试验。
BMJ Open. 2023 Dec 14;13(12):e075803. doi: 10.1136/bmjopen-2023-075803.
9
Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study.托珠单抗用于入住重症监护病房的新冠肺炎患者：一项回顾性研究。
Med J Islam Repub Iran. 2023 Aug 28;37:92. doi: 10.47176/mjiri.37.92. eCollection 2023.
10
High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells.高CBD大麻提取物通过miRNA介导的沉默作用抑制人小肠上皮细胞中促炎因子的表达。
Heliyon. 2023 Aug 5;9(8):e18817. doi: 10.1016/j.heliyon.2023.e18817. eCollection 2023 Aug.

本文引用的文献

1
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
2
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.托珠单抗治疗新冠肺炎合并肺炎住院患者的疗效。
N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.
3
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
4
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
5
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.

COVID-19 住院患者使用托珠单抗的疗效：CORIMUNO-TOCI-1 随机临床试验的随访。

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.

机构信息

Department of Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.

Université Paris-Saclay, Institut national de la santé et de la recherche médicale (INSERM) UMR1184, Le Kremlin Bicêtre, Le Kremlin Bicêtre, France.

出版信息

JAMA Intern Med. 2021 Sep 1;181(9):1241-1243. doi: 10.1001/jamainternmed.2021.2209.

DOI:10.1001/jamainternmed.2021.2209
PMID:34028504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8145157/
Abstract

This follow-up study of the CORIMUNO-TOCI-1 randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab.

摘要

本研究为 CORIMUNO-TOCI-1 随机临床试验的随访研究，旨在探讨 COVID-19 住院患者接受托珠单抗治疗后，生存状况与 C 反应蛋白水平之间的相关性。